



Investor Webcast
FY 2024 Results
and Highlights
19 March 2025



Your speakers today



Kevin Helash
Chief Executive Officer



Douglas Minder
Chief Finance Officer

Disclaimer



This presentation, including the oral presentation (together, the “Materials”) has been prepared by the management of Biotalsys NV (the “Company”). The Materials must be treated confidentially and may not be distributed, passed on or otherwise disclosed. The Materials serve information purposes only and do not constitute a prospectus or any offer for sale or subscription of, or solicitation or invitation to buy or subscribe for, any securities of the Company. The Company’s business, operations, financial situation and prospects are subject to risks and uncertainties. A description of the most important risks and uncertainties can be found in the Company’s annual report available on its website (www.Biotalsys.com)

This presentation includes market share and industry data, which were obtained by the Company from industry publications, press releases, data published by government agencies, industry reports prepared by consultants and other market data providers and internal surveys. The third party sources the Company has used generally state that the information they contain has been obtained from sources believed to be reliable. Some of these third party sources also state, however, that the accuracy and completeness of such information is not guaranteed and that the projections they contain are based on significant assumptions. As the Company does not have access to the facts and assumptions underlying such market data, or statistical information and economic indicators contained in these third party sources, the Company is unable to verify such information and, while the Company believes it to be reliable, it cannot guarantee its accuracy or completeness.

In addition, certain information in this document is not based on published data obtained from independent third parties or extrapolations therefrom, but rather is based upon the Company’s best estimates, which are in turn based upon information obtained from trade and business organizations and associations, consultants and other contacts within the industries in which the Company operates, information published by its competitors and its own experience and knowledge of conditions and trends in the markets in which it operates. The Company cannot provide any assurance that any of the assumptions that it has made while compiling this data from third party sources are accurate or correctly reflect its position in the industry and none of its internal estimates have been verified by any independent sources. The Company makes no representation or warranty as to the accuracy or completeness of this information. The Company has not independently verified this information and, while the Company believes it to be reliable, it cannot guarantee its accuracy.

You are responsible for protecting yourself against viruses and other destructive items. You are accessing the Materials is at your own risk and it is your responsibility to take precautions to ensure that they are free from viruses or other items of a destructive nature.

The Materials are provided in conjunction with the oral presentation held by the Company and should not be taken out of context.

The information contained in the Materials is subject to change without prior notice. The presentation of the Materials (or any part hereof) shall not create any implication that there has been no change in the information contained in the Materials since the date hereof or that there has been no change in the business or financial position of the Company or its subsidiary since the date hereof. The Company does not undertake to provide any additional information, update or keep current information contained in the Materials, or to remedy any omissions in or from the Materials and any opinions expressed in the Materials are subject to change without prior notice. The foregoing is in any event without prejudice to the Company’s obligations under applicable law in relation to disclosure.

The Materials contain certain forward-looking statements, sometimes identified by the words “believes,” “expects,” “predicts,” “intends,” “projects,” “plans,” “estimates,” “aims,” “foresees,” “anticipates,” “targets,” and similar expressions, which speak only as at the date of the Materials. Such statements reflect current views with respect to future events and are subject to risks and uncertainties. Forward-looking statements are based on current plans, estimates, projections and expectations. These statements are based on certain assumptions that may prove to be erroneous. No representations or warranties, express or implied, are given as to the achievement or reasonableness of, and no reliance should be placed on, such forward-looking statements, including any projections, estimates forecasts or targets contained herein.

Nothing in this presentation constitutes an offer of securities for sale in the EEA, the United Kingdom, Switzerland, Japan, the United States or elsewhere. The securities of the Company are not registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered, sold or otherwise transferred within the United States (as such term is defined in Regulation S under the Securities Act) unless registered under the Securities Act or pursuant to an exemption from such registration. There is no intention to register securities of the Company under the Securities Act.

You acknowledge that all industrial and intellectual property rights to this presentation are and shall remain vested in the Company. By attending this presentation or accessing the Materials you shall not acquire any right, title, license to use, or interest in the presentation or the Materials.

All of the trademarks, service marks and logos displayed in the Materials, including but not limited to Biotalsys, AGROBODY, EVOCA are registered and unregistered trademarks of the Company or one of its affiliates. Except as expressly provided in the Materials, you may not reproduce, display or otherwise use trademarks without first obtaining the Company’s written permission.

Biotalsys and each of their logos are commercial names, trademarks or registered trademarks owned by Biotalsys NV.

2024 highlights

- EVOCA
- Pipeline
- People
- Finance
- Mission



Kevin Helash, CEO




Looking ahead to 2025

- 4 key initiatives:
 - Securing regulatory approvals
 - Expanding our pipeline
 - Working towards commercialization of our portfolio
 - Maintaining strict financial discipline



Regulatory approval process continues to advance



Regulatory packages filed in US and EU;



1st phase in EU finalized with favorable advice from NL regulator














Novel nature of the technology requires in-depth review, but also sets standard for future approvals of protein-based biocontrols



Ongoing dialogue with agencies to clarify outstanding items

Innovative pipeline of biofungicides and bioinsecticides

Program	Target	Market	Global Market Size	Discovery	Development	Registration	Partnership Agreement
 EVOCA 1 st Gen	Botrytis, powdery mildew	High-value fruits & vegetables	Pilot product		●	--- 	
 EVOCA Next Gen	Botrytis, powdery mildew	High-value fruits & vegetables	\$2.4B		●		novonosis 
 BioFun-6	Botrytis, powdery mildew, potential other fungi	High-value fruits & vegetables	\$2.4B	●	→		Discussions ongoing
 BioFun-7	Cercospora spp. (leafspot disease)	Cowpeas and other legumes	<\$300M	●			Gates Foundation
 BioFun-4	Oomycetes (water mold)	Potatoes / High-value fruits & vegetables	\$2B	●			
 BioFun-8	Alternaria spp.	Fruits & vegetables and specialty crops	\$1.1B	●			
 BioIns-2	Key insect pests	Non-disclosed	N/A	●			

Total market value current pipeline estimated at >\$5.8B

1 new program per year resulting in +10 AGROBODY biocontrols to be launched on the market by 2040

Strict financial discipline

Biotaly's will maximise the impact of its time, equipment, investments, and cash to support its most critical initiatives



Douglas Minder, CFO



Key financials – FY 2024

In € thousand	December 31, 2024	December 31, 2023
Other operating income	3,183	2,611
Research and development expenses	(10,959)	(16,608)
General and administration expenses	(5,716)	(6,894)
Operating loss	(13,492)	(20,891)
Loss of the period	(13,188)	(20,510)
Basic and diluted loss per share (in EUR)	(0.40)	(0.65)
Net cash inflow (outflow) for the period	1,068	(12,521)
Cash and cash equivalents	22,638	21,570

Conclusion and Q&A



Kevin Helash
Chief Executive Officer



Douglas Minder
Chief Finance Officer

